It’s our mission to increase human life expectancy through intelligence driven biosystem simulations to truly personalize patient treatment.
Fueling the acceleration of research and development in drug discovery, we create the tools needed for unprecedented medical breakthroughs to take place much earlier in the drug discovery and development timeline. It’s our intention to create innovative products in the medical industry that will increase the efficiency and effectiveness of healthcare worldwide.
`
The first generation of new standard of the pharmaceutical industry is upon us.
It’s powered by
iSIM
Machine Learning Intelligence System
Ideal intersection of desirable ML features
Our Team Meet the team behind the tech
Jo Varshney
DVM/PhD, Founder & CEO
Hal Eisen
VP of Eng
Victor Antontsev
Biomedical Eng, Lead Modeling & Simulation Scientist
Neha Maharao
PhD Pharmaceutical Sciences, Lead DMPK Scientist
Luke Ceo
MSc. Organic Chemistry/MBA, Head of Business Development & Operations
Yogesh Bundey
MS CS / Data Science, AI/Machine Learning Engineer
Bo Yuan
MS Computer Science, Senior Full Stack Software Engineer
Jason Walsh
MS Physics / CS, Senior Software Engineer
Priyanka Arora
PhD Pharmaceutical Sciences, DMPK Scientist
Tolu Junaid
MD/PhD, Medical information
Advisors
Alexander Harmsen
CEO-Iris Automation, Technical AI advisor
“VeriSIM will have a tremendous impact on the pharma space by raising the bar for what can be done in pre-clinical research, and improving upon a conventional process to become a computable efficient process”
Jared Seehafer
CEO-Enzyme, FDA compliance advisor
“Data from animal studies is often a rate-limiting step in the development of new drugs and medical devices. The promise of generating this data programmatically, without either the time or the ethical considerations involved in testing with live animals, will revolutionize the development of new medicines, and I believe that VeriSIM is the company that will make this revolution a reality”
VeriSIM Life is providing pharmaceutical scientists a competitive advantage to accelerate R&D decisions to bring more personalized drugs in the market.
OUR CUSTOMERS:
Save millions of dollars in R&D while drastically reducing the need for excessive and unreliable animal clinical trials
Our customers recognize an average cost reduction of 50%.
Save years of time identifying compounds for potential treatment options and cure for diseases
Our customers save years by narrowing the sample size of which compounds to test.
Recognize accuracy and efficiency, far beyond what’s seen in animal testing
Our customers see improvements in efficiency and an increase in the number of new successful formulas
CURRENT
With BIOiSIM
BIOiSIM is offering unprecedented value for the drug development industry
by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illness or disease.
Toxic drugs excluded,
saves time, $$$, and lives
What are people (or scientists) saying about VeriSIM Life?
“The cost and time of developing new medications have been growing for decades. Modeling and simulation approaches have potential to reduce the time and cost and restore sustainability to drug development. VeriSIM Life is on the leading edge of this next phase of drug development using AI and machine learning to more efficiently and effectively predict pharmacology of potential new drug candidates through pharmacokinetic and pharmacodynamic modeling and simulation. VeriSIM Life has the potential to help design better drugs, predict disease outcome, and select patients who would benefit from therapies; making the dream of personalized medicine a reality.”
(Eric Stefanich, Director-PK/PD – Genentech)
(Dr. Anindya Bagchi, PhD – Prof. SBP Medical Discovery institute)
Our Partners and Supporters
We are partnering with top Pharmas and Academic labs to help de-risk R&D decisions and bring personalized new drugs to the market at a significant higher and accurate pace”
If you are looking to give your pharmaceutical company a competitive edge, GET IN TOUCH.
Our Investors
